Abstract Background Direct oral anticoagulants (DOACs) are the preferred treatment for
venous thromboembolism (VTE). However, DOAC use in patients with a BMI greater than 40 …

Current literature on the safety and efficacy of direct oral anticoagulants (DOACs) in patients
of extreme weights are limited, however, they are still being prescribed in these populations …

Background: Direct oral anticoagulants (DOACs) are known to have similar efficacy with a
decreased risk of bleeding when compared to warfarin for the treatment of venous …

Methods We utilized the Health Facts Center National Data Warehouse (Cerner) to perform
a retrospective analysis of patients with VTE (acute deep venous thrombosis (DVT) or …

Background Direct oral anticoagulants'(DOAC) pharmacokinetics are affected by obesity.
Their efficacy and safety in obesity (BMI≥ 30 kg/m 2) and morbid obesity (BMI≥ 40 kg/m 2) …

Abstract Study Objective Direct oral anticoagulants are the standard of care for venous
thromboembolism (VTE) treatment. These agents are recommended regardless of patient …

Background: Obesity is a well-known risk factor for venous thromboembolism (VTE),
however, obese patients are under-represented in clinical trials (1; 2). Four direct oral …

Background: Current venous thromboembolism guidelines recommend using direct oral
anticoagulants (DOACs) over warfarin regardless of obesity status; however, evidence …

Introduction: Limited data exists on the safety and efficacy of direct‐acting oral
anticoagulants (DOAC) use in morbidly obese patients with venous thromboembolism …

In clinical practice, direct oral anticoagulants (DOACs) are increasingly used for venous
thromboembolism treatment and prevention. A substantial proportion of patients with venous …